

Viral Hepatitis Prevention Board Meeting

Sevilla, Spain, March 11-12, 2004

Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes

Immune memory after hepatitis B vaccination


**Wolfgang Jilg
Institute for Medical Microbiology and Hygiene
University of Regensburg**

what is memory?

immunologic memory

- cardinal feature of the *adaptive* immune system
- ability to respond *again* to an antigen with a *more rapid, larger and qualitatively different* response (*anamnestic response*)

production of anti-HBs during Hep B vaccination



immunologic memory

role for hepatitis B immunisation


- **responsible for height and persistence of anti-HBs after third (booster) dose**
- **protects against disease after loss of anti-HBs in successfully vaccinated individuals**
- **may play a role for protection against antibody-escape mutants (as long as T-cell epitopes are not involved)**

persistence of anti-HBs

protection after Hep B vaccination


- *protection against infection* bound to anti-HBs-concentrations ≥ 10 IU/l
persistence depends on initial (peak) anti-HBs concentration

decrease of anti-HBs in 4 individuals after 3rd dose



Jilg et al, Lancet 1990; 335:173

percentage decrease of anti-HBs



kinetics of anti-HBs after hepatitis B vaccination

- very similar in every vaccinee *irrespective of the peak antibody level after the third vaccination*
- half-life of anti-HBs is *function of time*, being *very short initially* and *becoming longer with time* after last vaccination
- influenced by *disturbances to the immune system*, specific disorders (e.g. Down-Syndrome), certain drugs (e.g. antiepileptics)

how long does anti-HBs persist?

persistence of anti-HBs after hep.B vaccination

Population	time after first vacc.	anti-HBs ≥ 10 IU/l (%)
Alaskan natives (n=959) <i>Wainwright et al 1997</i>	10 yrs	76
Taiwanese children (n=539) <i>Wu et al 1999</i>	10 yrs	85
Italian children (n=223) <i>Mele et al 1999</i>	11-14 yrs	75
Chinese children (n=52) <i>Liao et al 1999</i>	15 yrs	50

in 10 - 50% of all successfully vaccinated individuals the anti-HBs concentration decreases below 10 IU/l within 10 years

*as protection against infection is bound to anti HBs concentrations above 10 IU/l these individuals are **again susceptible to infection***

break-through infections

10-year follow-up after Hep B vaccination in high-risk infants

972 Taiwanese children of HBsAg-positive mothers

→ HBIG at birth + vaccine at month 0,1, 6

**4 different doses of plasma-derived vaccine tested
(2.5 / 5 / 10 / 20 µg)**

month 12:


805 children anti-HBs pos., HBsAg and anti-HBc neg.

after 10 years:

539 available for analysis


anti-HBs 10 years after HB vaccination

according to anti-HBs level at 12 months (Wu et al 1999)



Wu et al JID 1999; 179: 1319

infection rate 10 yrs after HB-vaccination according to anti-HBs level at 12 months (Wu et al 1999)



break-through infections in successfully vaccinated individuals

population	time after 1 st vaccination	n (%) positive for anti-HBc	HBsAg
homosex. men (n=634) <i>Hadler et al 1991</i>	7-9 yrs	46 (7)*	2 (0.3)**
eskimos in Alasca (n=1630) <i>Wainwright et al 1997</i>	10 yrs	13 (0.8)*	0
children in Taiwan (n=805) <i>Wu et al 1999</i>	10 yrs	109 (14)*	4 (0.5)
children in Gambia (n=731) <i>Whittle et al 2002</i>	14 yrs	79 (11)*	2 (0.3)

* clinically silent

** HIV-positive


break-through infections after successful Hep B vaccination

- risk of hepatitis B infection is *inversely related to the maximal antibody response* to vaccine
- risk of infection *increases with declining anti-HBs*
- vast majority of infections in successfully vaccinated individuals are *clinically silent*
- protection against clinically important disease *outlasts the presence of detectable antibodies*

*Hadler et al, NEJM 1986; 315: 209;
Wu et al JID 1999; 179: 1319*

*Wainwright et al, JID 1997; 175: 674;
Whittle et al BMJ 2002; 325: 569*

protection after Hep B vaccination



protection against disease due to presence of immunologic memory


- vaccination induces *B- and T-memory cells*
 - rapid proliferation after contact with antigen, production of cytokines and specific antibodies (*„anamnestic response“*)
- in case of infection the anamnestic response prevents its further spread, downregulates viral replication and finally eliminates the virus
 - *prevents disease and chronic infection*

how can we prove the presence of an immunologic memory ?

methods to demonstrate immunologic memory after hepatitis B vaccination

- ***anamnestic anti-HBs response*** after revaccination

anamnestic response 17 years after HepB vacc.



within 8 days anti-HBs increases from 80 IU/l to 25 000 IU/l

>300 fold increase in anti-HBs

*mean increase of 130 IU per hour
or 2 IU per min*

anamnestic response to revaccination of 203 individuals ≥ 10 years after first Hep B-vaccination


group	time after first vaccination	anamnestic response at (%)
ital. children (n =147*) <i>Da Villa et al 1996</i>	10 years	96
ital. children (n =17*) <i>Resti et al 1997</i>	10 years	100
US children (n =14) <i>West et al 1994</i>	12 years	100
US children/adults (n =25**) <i>Watson et al 2001</i>	13 years	100

*** all anti-HBs neg.**


**** 5 anti-HBs neg.**

anamnestic response to booster doses with 2.5 or 10 µg HBsAg in previously immunized HCW (n=59)


day 10 day 30



baseline anti-HBs: <10 IU/I




baseline anti-HBs: 10-50 IU/I



revaccination of 131 individuals 2-6 years after basic immunization

anamnestic response to revaccination is correlated to primary response but on a higher level

anamnestic response to administration of non-absorbed HBsAg in responders to HB vacc. after loss of anti-HBs




anamnestic anti-HBs response after revaccination

- **present in >95% of vaccinees for at least 10 years after basic immunization**
- **correlated with primary response**
- **strength of response depends on antigen dose**

methods to demonstrate immunologic memory after hepatitis B vaccination

- ***anamnestic anti-HBs response*** after revaccination
- demonstration of ***anti-HBs-secreting B-cells*** in vitro (ELI-spot)

in vitro anti-HBs production by B cells after vaccination against hepatitis B (n=51)




methods to demonstrate immunologic memory after hepatitis B vaccination

- ***anamnestic anti-HBs response*** after revaccination
- demonstration of ***anti-HBs-secreting B-cells*** in vitro (ELI-spot)
- demonstration of ***HBsAg-specific T-cells***
 - proliferation assays
 - cytokine secreting cells (ELI-spot)
 - intracellular cytokines (FACS-analysis)

T cell proliferative response to HBsAg

in 31 HCW vaccinated 3-12 years before against hepatitis B


T cell proliferation positive individuals



T cell proliferative response to HBsAg

in 31 HCW vaccinated 3-12 years before against hepatitis B

T cell proliferation: mean counts per minute



T cell immunity of Hep B vaccinees before and after a booster 10 yrs after basic immunization

- 100 children (born to HBeAg pos. mothers) immunized at birth were tested after 10 years
- 21 (21%) were found to be negative for anti-HBs
- a subgroup was *tested for cellular immunity* by stimulation of PBMCs with HBsAg
- on revaccination *all showed a clear anamnestic anti-HBs response*

T cell immunity of Hep B vaccinees before and after a booster 10 yrs after basic immunization

	before booster no. pos./no. tested	after booster no. pos./no. tested
T-cell proliferation	29/58 (50%)	27/46 (59%)
IL-2 production	42/52 (81%)	14/16 (87%)
IL-5 production	41/41 (100%)	13/13 (100%)

Immunologic memory after Hep B vaccination

- presence of HBsAg specific T- and B-cell memory in in successfully vaccinated individuals documented for at least 10 years
- primary immune response seems to be a good predictor for the quality of immunologic memory *
- question about long term protection can only be answered by future long term follow-up studies looking for *break-through infections* and investigating the *humoral and cellular basis for immunologic memory*

* Banatvala et al, Vaccine 2001: 19: 877

difficulties in determining the length of protection

- follow-up studies with an observation time of >>10 years still rare
- number of vaccinees available for follow up decreases with time - data become less significant
- in low endemicity countries risk of hepatitis B very low - clinically significant break-through-infections (as sign of waning immunity) will be rare
- immunologic memory so far mainly demonstrated by anamnestic response to revaccination - reliable and sensitive cellular tests only seldom used

